Objective: To observe the levels of Guanxin Tongmai capsule on interleukin 6(IL-6)

tumor kecrosis fator-α(TNF-α)

endothelial cells micro particles(EMPs) and von willebrand factor(vWF) in patients with coronary heart disease and the action mechanism of Guanxin Tongmai capsule. Method :Sixty patients were divided randomly into treatment group(Guanxin Tongmai capsule 3# Tid) and control group(Tongxinluo capsule 3# Tid). After 4 weeks treatment

the results of IL-6

TNF-α

EMPs and vWF and the clinical effects were compared between the two groups. Result :There were no significant difference between the treatment group(85.7%)and the control group(90.0%) on ECG

no significant difference between the treatment group(92.9%)and the control group(93.3%) on clinical effect. The content of IL-6

TNF-α

EMPs and vWF in the two groups were both significantly decreased after treatment

no statistically significant difference between the two groups. Conclusion :Guanxin Tongmai capsule could decrease the content of IL-6

TNF-α

EMPs and vWF in the patients with coronary heart disease. Guanxin Tongmai capsule can play a considerable role compared with Tongxinluo capsule

the action mechanism may be anti-inflammatory.